alexa Combination Therapy To Preserve Residual Insulin Secretion In Type 1 Diabetes
ISSN: 2155-6156

Journal of Diabetes & Metabolism
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

5th World Congress on Diabetes & Metabolism
November 03-05, 2014 Embassy Suites Las Vegas, USA

Johnny Ludvigsson
ScientificTracks Abstracts: J Diabetes Metab
DOI: 10.4172/2155-6156.S1.026
Abstract
Introduction: Several mechanisms are involved in the pathogenetic process leading to insulin deficiency in Type 1 diabetes (T1D). Overwhelming insulin demand contributes to endoplasmatic reticulum stress, reduced function of the beta cells and increased sensitivity to a toxic immunologic milieu. Increased blood glucose, infections and obesity may contribute to a harmful inflammation. Autoimmunity, primary or secondary, then seems to add the ultimate blow. We therefore perform a pilot-trial where we combine beta cell protection, anti-inflammatory treatment and immune modulation. Patients and design: 60 Patients 10-18 years old with T1D since <4 months, fasting C-peptide >0.12 nmol/l and GADA positive all get intensive insulin treatment and strict blood glucose control to decrease beta cell stress. In addition they are randomized in a double-blind trial into one of four arms: A. Day 1-90 Ibuprofen 400 mg/d + Vitamin D 2000 U/d Day 1-450 + GAD-alum 20 mikrogsc Day 15 and 45. B. The same as A but placebo instead of Ibuprofen. C. The same as C but 40 instead of 20 mikrog GAD-alum. D: Placebo. Results: Only some patients have passed 6 month visit, but so far minimal treatment related adverse events. Several patients low insulin requirement and HbA1c within normal range (<43 mmol/mol). Data will be presented in Nov-2014. Conclusion: Combination of several treatment modalities, which as single therapy have insufficient efficacy, may offer safe alternatives to preserve residual insulin secretion.
Biography
Johnny Ludvigsson, is a full Professor of Pediatrics, Link?ping University. He performed the first immune intervention ever in T1D with plasmapheresis (BMJ 1983) which lead to the discovery of 64kD (Nature 1982), later shown to be GAD. He performed a number of different immune interventios both with GAD-alum (NEJM 2008, NEJM 2012) and AntiCD3 monoclonal antibodies (Lancet 2011). More than 430 scientific publications also on diabetic complications (NEJM 1994), and is the main tutor of >20 PhD students. He was the first pediatrician ever as Honorary member of EASD.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords